Physician profile
Alexander Greff
NPI 1578182564
$4,037.57
in general payments reported to CMS, 2019-2025
24 companies · $984 in 2025
The $984 reported for 2025 was more than what 83% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $581 · 2022: $821 · 2023: $709 · 2024: $943 · 2025: $984.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,574 · Education: $61.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,573.58 |
| Education | $61.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $1,342.03 | 2021-2025 | Cuvitru, Hyqvia, Eohilia |
| Astrazeneca Pharmaceuticals LP | $686.12 | 2021-2025 | Fasenra, Tezspire, Airsupra |
| Genzyme Corporation | $295.02 | 2022-2025 | |
| Glaxosmithkline, LLC. | $273.82 | 2021-2025 | Nucala, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $210.93 | 2021-2025 | |
| Csl Behring | $189.33 | 2023-2025 | Haegarda, Hizentra, Andembry |
| Genentech USA, INC. | $150.55 | 2021-2025 | Xolair |
| Octapharma USA, INC. | $108.42 | 2022-2025 | Octagam Immune Globulin (Human) |
| Optinose US, INC. | $105.88 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $98.15 | 2022-2025 | Dupixent |
| Kaleo, INC. | $80.96 | 2021-2024 | Auvi-Q |
| Amgen INC. | $76.08 | 2022-2025 | Tezspire |
| Biocryst US Sales Co., LLC | $72.99 | 2021-2024 | Orladeyo |
| Ars Pharmaceuticals Operations, INC. | $62.92 | 2025 | Neffy |
| Sanofi-Aventis U.S. LLC | $61.99 | 2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cycle Pharmaceuticals INC | $52.37 | 2024-2025 | Sajazir |
| Grifols USA, LLC | $46.84 | 2024 | Xembify |
| Janssen Pharmaceuticals, INC | $22.78 | 2023 | Spravato |
| Pfizer INC. | $20.96 | 2022 | |
| Azurity Pharmaceuticals, INC. | $18.00 | 2025 | Alvesco |
| Bio Products Laboratory USA, INC. | $16.42 | 2021 | |
| Leo Pharma INC. | $15.43 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.09 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $14.49 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Greff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.